

Heart Failure Devices Global Market - Forecast to 2029

<https://marketpublishers.com/r/H46F9603C2FFEN.html>

Date: March 2023

Pages: 654

Price: US\$ 4,950.00 (Single User License)

ID: H46F9603C2FFEN

Abstracts

Heart Failure Devices (HFD) Heart failure occurs when the heart muscle does not pump blood as well as it should, when this happens blood often backs up and causes shortness of breath. In some people, the heart has difficulty pumping enough blood to support other organs in the body. Others may have a hardening and stiffening of the heart muscle itself, which blocks or reduces blood flow to the heart.

According to IQ4I analysis, the heart failure devices global market expected to grow at high single-digit CAGR from 2022 to 2029 to reach \$38,879.9 million by 2029. Factors such as increasing incidence of heart failure diseases, technological advancement in heart failure devices, rising geriatric population, and favorable reimbursement are the drivers, vast pipeline products, increase in funding and approvals are the opportunities. Adverse events and complications with the implantation of heart failure devices, the high cost of the devices, and the lack of trained professionals are the restraints, whereas, stringent regulatory guidelines and the availability of alternative products are the threats.

The heart failure devices global market is segmented based on products, end-users, surgery and geography. The heart failure devices market based on products is segmented as cardiac rhythm products, cardiac assist devices (CAD), structural heart devices (SHD), ECMO and others (modulation devices). Among them, the structural heart device segment commands the largest revenue in 2022 and it is expected to grow at double digit CAGR from 2022 to 2029.

The cardiac rhythm products based on product type is segmented into Implantable Cardioverter Defibrillators (ICD), pacemakers and Cardiac Resynchronization Therapy (CRT) devices. Among them, the ICD segment commanded the largest revenue in 2022 and it is expected to grow at mid single-digit CAGR from 2022 to 2029. The CRT segment is expected to grow at mid single digit CAGR from 2022 to 2029. The

Implantable Cardioverter Defibrillators (ICDs) are further segmented into Single and dual-chamber ICDs, among which, dual-chamber devices accounted for the largest revenue in 2022 and is expected to grow at mid single digit CAGR from 2022 to 2029. The pacemakers are segmented into single and dual-chamber pacemakers, among which, dual chamber accounted for the largest revenue in 2022 and is expected to grow at low single digit CAGR from 2022 to 2029. The CRT global market is expected to grow at mid single digit CAGR from 2022 to 2029. The CRT is further segmented into CRT-P and CRT-D; among which, CRT-D accounted for the largest revenue in 2022 and is expected grow at mid single digit CAGR from 2022 to 2029.

Cardiac assist devices based on products are segmented into Ventricular Assist Devices (VAD), Intra aortic balloon pumps (IABP) and Total Artificial Heart (TAH). The Ventricular Assist Devices (VAD) commanded the largest revenue of the Cardiac assist devices global market based on the product in 2022 and is expected to grow at double digit CAGR from 2022 to 2029. VAD based on product type is further sub-segmented into Left-VAD (LVAD), Right-VAD (R-VAD), and Bi-VAD, among which, LVAD has the largest revenue in 2022 and is expected to grow at double digit CAGR from 2022 to 2029.

The structural heart devices are segmented into repair devices and replacement devices, among which, the replacement device segment accounted for the largest revenue in 2022 and is expected to grow at double digit CAGR from 2022 to 2029. Repair devices are expected to grow at early teen CAGR from 2022 to 2029. The repair devices are segmented into annuloplasty, valvuloplasty, occluders, Transcatheter Mitral Valve Repair (TMVr) and others (Chordal replacement, TTVR, Ventricular restoration system, & Shunt), among these, occluders segment accounted for the largest revenue in 2022 and is expected to grow at a mid teen CAGR from 2022 to 2029. The TMVr segment is expected to grow at mid teen CAGR from 2022 to 2029. The heart valve replacement techniques are broadly classified into surgical and transcatheter-based techniques, among which the transcatheter valve segment accounted for the largest revenue in 2022 and is expected to grow strong at double digit CAGR from 2022 to 2029. The surgical technique is further segmented into mechanical valves and tissue valves, among which, the tissue heart valve segment accounted for the largest revenue in 2022. The transcatheter valve replacement devices global market is segmented into Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral Valve Replacement (TMVR) and Transcatheter Pulmonary Valve Replacement (TPVR), among which TAVR segment occupies the largest share in 2022 and TMVR device segment is expected to grow at a high double digit CAGR from 2022 to 2029.

Heart Failure Devices global market based on surgery is segmented into open surgery, minimally invasive surgery and robotic surgery, among these, the open surgery segment accounted for the largest revenue in 2022 and is expected to grow at high single digit CAGR from 2022 to 2029. Robotic surgery is the fastest-growing segment and is expected to grow at high teen CAGR from 2022 to 2029.

Heart Failure Devices global market based on end-users is segmented into hospitals, ambulatory surgical centers (ASC) and others (academics & research institutes and OBL). Among end-users, the hospital segment accounted for the largest revenue in 2022 and is expected to grow at high single digit CAGR from 2022 to 2029. The ambulatory surgical center is the fastest-growing segment and is expected to grow at early teen CAGR from 2022 to 2029.

The heart failure devices market based on region is segmented as North America (U.S. and the Rest of North America), Europe (Germany, France, Italy, and the Rest of Europe), Asia-Pacific (Japan, China, India and the Rest of APAC), and the Rest of the world (Brazil, Rest of LATAM and the Middle East & Africa). North America holds the largest revenue in 2022 and it is expected to grow at high single digit CAGR from 2022 to 2029 mainly due to the increasing prevalence of structural heart diseases in the region, persistently elevating geriatric population burdened with various kinds of valvular diseases, increasing preference and adoption of the patient population there for technologically advanced and minimally invasive therapeutic products, availability of advanced imaging and better patient screening programs and increasing investments on research activities for developing innovative and technologically advanced products.

The Asia-Pacific is the fastest-growing region and is expected to grow in double digit CAGR from 2022 to 2029 due to the high structural heart disease burden in the region, increasing geriatric population, increasing demand for better healthcare facilities, increasing penetration of reimbursement schemes in developing countries, increasing demand for highly efficient and minimally invasive products from the value-centric patient population, growing economies of the region, availability of various kinds of heart failure treatment products, increasing patient awareness of these products and increasing medical tourism prospects of the region.

The heart failure devices global market is a consolidated market with the top 8 players occupying XX% of the market hence all the existing players in this market are involved in developing new and advanced therapeutics to maintain their market shares. Some of the major players in the heart failure devices market include Medtronic PLC (Ireland), Abbott Laboratories (U.S.), Edwards Lifesciences Corporation (U.S.), Boston Scientific

Corporation (U.S.), Abiomed (U.S.), Biotronik (Germany), Getinge (Sweden) and MicroPort (China).

Contents

1 EXECUTIVE SUMMARY

2 INTRODUCTION

2.1 KEY TAKEAWAYS

2.2 SCOPE OF THE REPORT

2.3 REPORT DESCRIPTION

2.4 MARKETS COVERED

2.5 STAKEHOLDERS

2.6 RESEARCH METHODOLOGY

2.6.1 MARKET SIZE ESTIMATION

2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION

2.6.3 SECONDARY SOURCES

2.6.4 PRIMARY SOURCES

2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES

2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES

2.6.7 ASSUMPTIONS

3 MARKET ANALYSIS

3.1 INTRODUCTION

3.2 MARKET SEGMENTATION

3.3 FACTORS INFLUENCING MARKET

3.3.1 DRIVERS AND OPPORTUNITIES

3.3.1.1 Increasing incidence of heart failure

3.3.1.2 Technological advancements in heart failure devices

3.3.1.3 Rising geriatric population

3.3.1.4 Vast pipeline products

3.3.1.5 Increase in product approvals

3.3.1.6 Increase in funding

3.3.2 RESTRAINTS AND THREATS

3.3.2.1 Adverse events and complications with the implantation of heart failure devices

3.3.2.2 High cost of the devices

3.3.2.3 Lack of skilled and trained professionals

3.3.2.4 Stringent regulatory guidelines

3.3.2.5 Availability of alternative products

3.3.2.6 Increasing product recalls

3.4 REGULATORY AFFAIRS

3.4.1 COMMERCIALIZATION REGULATORY AFFAIRS

3.4.2 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION

3.4.2.1 ISO 9001: 2015 quality management system

3.4.2.2 ISO 14644-1 cleanroom standards

3.4.2.3 ISO 13485 medical devices

3.4.2.4 ISO 10993 biological evaluation of medical devices

3.4.2.5 ISO 14971: risk management of medical devices

3.4.2.6 ISO 5840: heart valve validation

3.4.2.7 ISO 14708-5: active implantable medical devices - part 5: circulatory support devices

3.4.2.8 IEC 60601-1 medical electrical equipment standard

3.4.2.9 IEC 60601-1-11 home care safety

3.4.2.10 ASTM international standards

3.4.3 U.S.

3.4.4 CANADA

3.4.5 EUROPE

3.4.6 CHINA

3.4.7 JAPAN

3.4.8 INDIA

3.5 CLINICAL TRIALS DATA

3.6 REIMBURSEMENT SCENARIO

3.6.1 REIMBURSEMENT TABLE

3.6.1.1 Structural heart device reimbursement

3.6.1.2 Rhythm management device implant procedures

3.6.1.3 Surgical valve repair and replacement procedures

3.6.1.4 Ventricular assist device reimbursement

3.6.1.5 CAD physician reimbursement

3.7 PORTER'S FIVE FORCE ANALYSIS

3.7.1 THREAT OF NEW ENTRANTS

3.7.2 THREAT OF SUBSTITUTES

3.7.3 BARGAINING POWER OF SUPPLIERS

3.7.4 BARGAINING POWER OF BUYERS

3.7.5 COMPETITIVE RIVALRY

3.8 PATENT ANALYSIS

3.9 TECHNOLOGICAL ADVANCEMENTS

3.9.1 BIONIC PACEMAKER

3.9.2 PULSE VAD

- 3.9.3 VADOVATIONS CARDIAC ASSIST SYSTEM
- 3.9.4 TOTAL ARTIFICIAL HEART (TAH)
- 3.9.5 FULLY IMPLANTED BIORESORBABLE CARDIAC PACEMAKERS WITHOUT LEADS AND BATTERIES
- 3.9.6 INTERATRIAL SHUNT
- 3.9.7 VAGUS NERVE STIMULATION
- 3.9.8 ELECTRICAL MICROCURRENT THERAPY
- 3.9.9 CONTRABAND
- 3.10 SUPPLY CHAIN ANALYSIS
- 3.11 FUNDING SCENARIO
- 3.12 PRODUCT APPROVALS
- 3.13 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
 - 3.13.1 HEARTFAILURE DEVICES GLOBAL MARKET SHARE ANALYSIS
 - 3.13.2 VENTRICULAR ASSIST DEVICES GLOBAL MARKET SHARE ANALYSIS
 - 3.13.3 INTRA-AORTIC BALLOON PUMP (IABP) GLOBAL MARKET SHARE ANALYSIS
 - 3.13.4 CARDIAC RESYNCHRONIZATION THERAPY GLOBAL MARKET SHARE ANALYSIS
 - 3.13.5 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS GLOBAL MARKET SHARE ANALYSIS
 - 3.13.5.1 Single chamber ICD
 - 3.13.5.2 Dual chamber ICD
 - 3.13.6 PACEMAKERS GLOBAL MARKET SHARE ANALYSIS
 - 3.13.6.1 Single chamber pacemaker
 - 3.13.6.2 Dual chamber pacemaker
 - 3.13.7 MARKET SHARE ANALYSIS OF ANNULOPLASTY REPAIR DEVICES BASED ON MAJOR PLAYERS
 - 3.13.8 MARKET SHARE ANALYSIS OF OCCLUDERS BASED ON MAJOR PLAYERS
 - 3.13.9 MARKET SHARE ANALYSIS OF MECHANICAL VALVE BASED ON MAJOR PLAYERS
- 3.14 PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION
 - 3.14.1 U.S. PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION ANALYSIS
 - 3.14.2 ITALY PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION ANALYSIS
 - 3.14.3 GERMANY PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION ANALYSIS

3.14.4 FRANCE PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD)
MARKET PENETRATION ANALYSIS

3.14.5 JAPAN PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET
PENETRATION ANALYSIS

3.15 INTRA-AORTIC BALLOON PUMP (IABP) TOTAL ADRESSABLE MARKET (TAM)
& MARKET PENETRATION

3.15.1 U.S. INTRA-AORTIC BALLOON PUMP (IABP) TOTAL ADDRESSABLE
MARKET (TAM) & MARKET PENETRATION ANALYSIS

3.15.2 ITALY INTRA-AORTIC BALLOON PUMP (IABP) TOTAL ADDRESSABLE
MARKET (TAM) & MARKET PENETRATION ANALYSIS

3.15.3 GERMANY INTRA-AORTIC BALLOON PUMP (IABP) TOTAL ADDRESSABLE
MARKET (TAM) & MARKET PENETRATION ANALYSIS

3.15.4 FRANCE INTRA-AORTIC BALLOON PUMP (IABP) TOTAL ADDRESSABLE
MARKET (TAM) MARKET PENETRATION ANALYSIS

3.15.5 JAPAN INTRA-AORTIC BALLOON PUMP (IABP) TOTAL ADDRESSABLE
MARKET (TAM) & MARKET PENETRATION ANALYSIS

3.16 STRUCTURAL HEART DEVICES TOTAL ADDRESSABLE MARKET (TAM),
MARKET PENETRATION, PREVALENCE, AND NUMBER OF PROCEDURES
PERFORMED

3.17 BAROREFLEX ACTIVATION THERAPY (BAT) MARKET PENETRATION,
PREVALENCE, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED

3.18 CARDIAC ASSIST DEVICES NUMBER OF UNITS SOLD BASED ON REGION

3.18.1 VENTRICULAR ASSIST DEVICES NUMBER OF UNITS SOLD BASED ON
REGION

3.18.1.1 Ventricular assist devices (vad) number of units sold

3.18.1.2 Percutaneous ventricular assist devices number of units sold

3.18.2 IABP DEVICES GLOBAL NUMBER OF UNITS SOLD BASED ON REGION

3.18.3 TOTAL ARTIFICIAL HEART NUMBER OF UNITS BASED ON REGION

3.19 STRUCTURAL HEART DEVICES NUMBER OF UNITS SOLD BASED ON
REGION

3.20 CARDIAC RHYTHM PRODUCTS NUMBER OF UNITS SOLD BASED ON
REGION

3.21 TAVR CENTERS

3.22 STRUCTURAL HEART DEVICES COMPANY COMPARISON TABLE BASED ON
PRODUCTS

3.22.1 TRANSCATHETER HEART VALVE COMPANY COMPARISON TABLE
BASED ON PRODUCT AND INDICATION

3.22.2 OCCLUDERS COMPANY COMPARISON TABLE BASED ON PRODUCTS
AND INDICATION

3.22.3 VALVULOPLASTY COMPANY COMPARISON TABLE BASED ON PRODUCTS AND INDICATION

3.22.4 ANNULOPLASTY COMPANY COMPARISON TABLE BASED ON PRODUCTS AND INDICATION

3.22.5 MECHANICAL HEART VALVES COMPANY COMPARISON TABLE BASED ON PRODUCTS AND INDICATION

3.22.6 TISSUE HEART VALVES COMPANY COMPARISON TABLE BASED ON PRODUCTS AND INDICATION

3.23 REUSE OF PACEMAKERS AND ICDS

3.24 TRICUSPID VALVE PIPELINE

3.24.1 CURRENT TREATMENT OPTIONS FOR TR MANAGEMENT

3.24.2 TRANSCATHETER TRICUSPID VALVE REPLACEMENT (TTVR)

3.24.2.1 Orthotopic implants pipeline

3.24.2.2 Heterotopic implants pipeline

4 HEART DEVICES GLOBAL MARKET, BASED ON PRODUCT

4.1 INTRODUCTION

4.2 CARDIAC RHYTHM PRODUCTS

4.2.1 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICDS)

4.2.2 SINGLE-CHAMBER ICD

4.2.3 DUAL-CHAMBER ICD

4.3 PACEMAKER

4.3.1 SINGLE-CHAMBER PACEMAKER

4.3.2 DUAL-CHAMBER PACEMAKER

4.4 CARDIAC RESYNCHRONIZATION THERAPY

4.4.1 CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR (CRT-D)

4.4.2 CARDIAC RESYNCHRONIZATION THERAPY PACEMAKERS (CRT-P)

4.5 NEW YORK HEART CLASSIFICATION AND CARDIAC RHYTHM THERAPY CHOICE

4.6 CARDIAC ASSIST DEVICE (CAD)

4.6.1 VENTRICULAR ASSIST DEVICES (VAD)

4.6.2 LEFT VENTRICULAR ASSIST DEVICES (LVAD)

4.6.3 RIGHT VENTRICULAR ASSIST DEVICES (RVAD)

4.6.4 BI-VENTRICULAR ASSIST DEVICES (BI-VAD)

4.6.5 INTRA-AORTIC BALLOON PUMP (IABP)

4.6.6 TOTAL ARTIFICIAL HEART (TAH)

4.7 STRUCTURAL HEART DEVICES (SHD)

4.7.1 REPAIR DEVICES

- 4.7.1.1 Annuloplasty repair devices
- 4.7.1.2 Valvuloplasty
- 4.7.1.3 Occluders
- 4.7.1.4 Transcatheter Mitral Valve repair (TMVr) devices
- 4.7.1.5 Other structural heart repair devices
- 4.7.2 REPLACEMENT DEVICES
 - 4.7.2.1 Surgical valve replacement devices
 - 4.7.2.1.1 Mechanical heart valves
 - 4.7.2.1.2 Tissue heart valves (biological valves)
 - 4.7.2.2 Transcatheter valve replacement devices
 - 4.7.2.2.1 Transcatheter Aortic Valve Replacement (TAVR)
 - 4.7.2.2.2 Transcatheter Mitral Valve Replacement (TMVR)
 - 4.7.2.2.3 Transcatheter Pulmonary Valve Replacement (TPVR)
- 4.8 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
- 4.9 OTHERS (BAT AND CCM TECHNOLOGY)
 - 4.9.1 BAROREFLEX ACTIVATION THERAPY
 - 4.9.2 CARDIAC CONTRACTILITY MODULATION (CCM)

5 HEART FAILURE DEVICES GLOBAL MARKET, BASED ON SURGERY

- 5.1 INTRODUCTION
- 5.1 ROBOTIC SURGERY
- 5.2 OPEN HEART SURGERY
- 5.3 MINIMALLY INVASIVE SURGERY

6 HEART FAILURE DEVICES GLOBAL MARKET, BASED ON END-USERS

- 6.1 INTRODUCTION
 - 6.1.1 HOSPITALS
 - 6.1.2 AMBULATORY SURGICAL CENTERS (ASCS)
 - 6.1.3 OTHER END-USERS

7 REGIONAL ANALYSIS

- 7.1 INTRODUCTION
- 7.2 NORTH AMERICA
 - 7.2.1 U.S.
 - 7.2.2 REST OF NORTH AMERICA
- 7.3 EUROPE

- 7.3.1 GERMANY
- 7.3.2 FRANCE
- 7.3.3 ITALY
- 7.3.4 REST OF EUROPE
- 7.4 APAC
 - 7.4.1 JAPAN
 - 7.4.2 CHINA
 - 7.4.3 INDIA
 - 7.4.4 REST OF APAC
- 7.5 REST OF THE WORLD
 - 7.5.1 BRAZIL
 - 7.5.2 REST OF LATAM
 - 7.5.3 MIDDLE EAST AND AFRICA

8 COMPETITIVE LANDSCAPE

- 8.1 INTRODUCTION
- 8.2 PRODUCT APPROVALS
- 8.3 ACQUISITIONS
- 8.4 NEW PRODUCT LAUNCH
- 8.5 INVESTMENT AND FUNDING
- 8.6 OTHER DEVELOPMENTS

9 MAJOR COMPANIES

- 9.1 ABBOTT LABORATORIES
 - 9.1.1 OVERVIEW
 - 9.1.2 FINANCIALS
 - 9.1.3 PRODUCT PORTFOLIO
 - 9.1.4 KEY DEVELOPMENTS
 - 9.1.5 BUSINESS STRATEGY
 - 9.1.6 SWOT ANALYSIS
- 9.2 ABIOMED
 - 9.2.1 OVERVIEW
 - 9.2.2 FINANCIALS
 - 9.2.3 PRODUCT PORTFOLIO
 - 9.2.4 KEY DEVELOPMENTS
 - 9.2.5 BUSINESS STRATEGY
 - 9.2.6 SWOT ANALYSIS

9.3 BIOTRONIK SE & CO. KG

9.3.1 OVERVIEW

9.3.2 FINANCIALS

9.3.3 PRODUCT PORTFOLIO

9.3.4 KEY DEVELOPMENTS

9.3.5 BUSINESS STRATEGY

9.3.6 SWOT ANALYSIS

9.4 BOSTON SCIENTIFIC CORPORATION

9.4.1 OVERVIEW

9.4.2 FINANCIALS

9.4.3 PRODUCT PORTFOLIO

9.4.4 KEY DEVELOPMENTS

9.4.5 BUSINESS STRATEGY

9.4.6 SWOT ANALYSIS

9.5 CORCYM

9.5.1 OVERVIEW

9.5.2 FINANCIALS

9.5.3 PRODUCT PORTFOLIO

9.5.4 KEY DEVELOPMENTS

9.5.5 BUSINESS STRATEGY

9.5.6 SWOT ANALYSIS

9.6 EDWARDS LIFESCIENCES CORPORATION

9.6.1 OVERVIEW

9.6.2 FINANCIALS

9.6.3 PRODUCT PORTFOLIO

9.6.4 KEY DEVELOPMENTS

9.6.5 BUSINESS STRATEGY

9.6.6 SWOT ANALYSIS

9.7 GETINGE

9.7.1 OVERVIEW

9.7.2 FINANCIALS

9.7.3 PRODUCT PORTFOLIO

9.7.4 KEY DEVELOPMENTS

9.7.5 BUSINESS STRATEGY

9.7.6 SWOT ANALYSIS

9.8 MEDTRONIC, PLC

9.8.1 OVERVIEW

9.8.2 FINANCIALS

9.8.3 PRODUCT PORTFOLIO

9.8.4 KEY DEVELOPMENTS

9.8.5 BUSINESS STRATEGY

9.8.6 SWOT ANALYSIS

9.9 MICROPORT SCIENTIFIC CORPORATION

9.9.1 OVERVIEW

9.9.2 FINANCIALS

9.9.3 PRODUCT PORTFOLIO

9.9.4 KEY DEVELOPMENTS

9.9.5 BUSINESS STRATEGY

9.9.6 SWOT ANALYSIS

9.10 TELEFLEX INCORPORATED

9.10.1 OVERVIEW

9.10.2 FINANCIALS

9.10.3 PRODUCT PORTFOLIO

9.10.4 KEY DEVELOPMENTS

9.10.5 BUSINESS STRATEGY

9.10.6 SWOT ANALYSIS

List Of Tables

LIST OF TABLES

TABLE 1 HEART FAILURE DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 2 VAD NUMBER OF UNITS SOLD, BASED ON REGION, (2022) (NO'S)

TABLE 3 PERCUTANEOUS VAD NUMBER OF UNITS SOLD, BASED ON REGION, (2021-2029) (NO'S)

TABLE 4 IABP NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO'S)

TABLE 5 TOTAL ARTIFICIAL HEART NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO'S)

TABLE 6 HEART FAILURE DEVICES (HFD) GLOBAL MARKET REVENUE, BASED ON PRODUCT (2021-2029) (\$MN)

TABLE 7 CARDIAC RHYTHM PRODUCTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 8 CARDIAC RHYTHM PRODUCTS GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) (\$MN)

TABLE 9 ICD GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 10 ICD GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) (\$MN)

TABLE 11 SINGLE-CHAMBER ICD GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 12 DUAL-CHAMBER ICD GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 13 PACEMAKER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 14 PACEMAKER GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) (\$MN)

TABLE 15 SINGLE-CHAMBER PACEMAKER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 16 DUAL-CHAMBER PACEMAKER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 17 CRT GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 18 CRT GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) (\$MN)

TABLE 19 CRT-D GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 20 CRT-P GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029)
(\$MN)

TABLE 21 CAD GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029)
(\$MN)

TABLE 22 CAD GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029)
(\$MN)

TABLE 23 VAD GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029)
(\$MN)

TABLE 24 VAD GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE
(2021-2029) (\$MN)

TABLE 25 LVAD GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029)
(\$MN)

TABLE 26 RVAD GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029)
(\$MN)

TABLE 27 BI-VAD GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029)
(\$MN)

TABLE 28 IABP GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029)
(\$MN)

TABLE 29 TAH GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029)
(\$MN)

TABLE 30 STRUCTURAL HEART DEVICES GLOBAL MARKET REVENUE, BASED
ON PRODUCTS (2021-2029) (\$MN)

TABLE 31 STRUCTURAL HEART DEVICES GLOBAL MARKET REVENUE, BASED
ON REGION, (2021-2029) (\$MN)

TABLE 32 REPAIR DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCT
TYPE, (2021-2029) (\$MN)

TABLE 33 REPAIR DEVICES GLOBAL MARKET REVENUE, BASED ON REGION,
(2021-2029) (\$MN)

TABLE 34 ANNULOPLASTY GLOBAL MARKET REVENUE, BASED ON REGION,
(2021-2029) (\$MN)

TABLE 35 VALVULOPLASTY GLOBAL MARKET REVENUE, BASED ON REGION,
(2021-2029) (\$MN)

TABLE 36 OCCLUDERS GLOBAL MARKET REVENUE, BASED ON REGION,
(2021-2029) (\$MN)

TABLE 37 LIST OF APPROVED TMVR PRODUCTS CURRENTLY AVAILABLE IN
THE MARKET

TABLE 38 PIPELINE OF TMVR PRODUCTS

TABLE 39 TMVR GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029)
(\$MN)

TABLE 40 OTHER REPAIR DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 41 REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 42 REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 43 SURGICAL VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 44 SURGICAL VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 45 MECHANICAL HEART VALVES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 46 TISSUE HEART VALVES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 47 TRANSCATHETER VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 48 TRANSCATHETER VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 49 LIST OF APPROVED TAVR PRODUCTS CURRENTLY AVAILABLE IN THE MARKET

TABLE 50 PIPELINE OF TAVR PRODUCTS

TABLE 51 TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 52 LIST OF APPROVED TMVR PRODUCTS CURRENTLY AVAILABLE IN THE MARKET

TABLE 53 PIPELINE OF TMVR PRODUCTS

TABLE 54 TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 55 LIST OF APPROVED TPVR PRODUCTS CURRENTLY AVAILABLE IN THE MARKET

TABLE 56 PIPELINE OF TPVR PRODUCTS

TABLE 57 TRANSCATHETER PULMONARY VALVE REPLACEMENT (TPVR) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 58 ECMO GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) (\$MN)

TABLE 59 OTHER HEART FAILURE DEVICES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) (\$MN)

TABLE 60 HEART FAILURE DEVICES GLOBAL MARKET REVENUE, BASED ON SURGERY (2021-2029) (\$MN)

TABLE 61 ROBOTIC SURGERY GLOBAL MARKET REVENUE, BASED ON REGION
(2021-2029) (\$MN)

TABLE 62 OPEN SURGERY GLOBAL MARKET REVENUE, BASED ON REGION
(2021-2029) (\$MN)

TABLE 63 MINIMALLY INVASIVE SURGERY GLOBAL MARKET REVENUE, BASED
ON REGION (2021-2029) (\$MN)

TABLE 64 HEART FAILURE DEVICES GLOBAL MARKET REVENUE, BASED ON
END-USERS, (2021-2029) (\$MN)

TABLE 65 HOSPITALS GLOBAL MARKET REVENUE, BASED ON REGION,
(2021-2029) (\$MN)

TABLE 66 AMBULATORY SURGICAL CENTERS GLOBAL MARKET REVENUE,
BASED ON REGION, (2021-2029) (\$MN)

TABLE 67 OTHER END-USERS GLOBAL MARKET REVENUE, BASED ON REGION,
(2021-2029) (\$MN)

TABLE 68 HEART FAILURE DEVICES GLOBAL MARKET REVENUE, BASED ON
REGION, (2021-2029) (\$MN)

TABLE 69 NORTH AMERICA HEART FAILURE DEVICES AVERAGE SELLING
PRICE (ASP) (\$) & NO. OF UNITS SOLD (2022)

TABLE 70 NORTH AMERICA HEART FAILURE DEVICES MARKET REVENUE,
BASED ON PRODUCTS, (2021-2029) (\$MN)

TABLE 71 NORTH AMERICA CARDIAC RHYTHM PRODUCTS MARKET REVENUE,
BASED ON PRODUCT TYPE (2021-2029) (\$MN)

TABLE 72 NORTH AMERICA CRT MARKET REVENUE, BASED ON PRODUCT TYPE
(2021-2029) (\$MN)

TABLE 73 NORTH AMERICA ICD MARKET REVENUE, BASED ON PRODUCT TYPE
(2021-2029) (\$MN)

TABLE 74 NORTH AMERICA PACEMAKER MARKET REVENUE, BASED ON
PRODUCT TYPE (2021-2029) (\$MN)

TABLE 75 NORTH AMERICA CAD MARKET REVENUE, BASED ON PRODUCTS
(2021-2029) (\$MN)

TABLE 76 NORTH AMERICA VAD MARKET REVENUE, BASED ON PRODUCT
TYPE, (2021-2029) (\$MN)

TABLE 77 NORTH AMERICA SHD MARKET REVENUE, BASED ON PRODUCTS
(2021-2029) (\$MN)

TABLE 78 NORTH AMERICA REPAIR DEVICES MARKET REVENUE, BASED ON
PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 79 NORTH AMERICA REPLACEMENT DEVICES MARKET REVENUE,
BASED ON PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 80 NORTH AMERICA SURGICAL VALVE MARKET REVENUE, BASED ON

PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 81 NORTH AMERICA TRANSCATHETER VALVE MARKET REVENUE,
BASED ON PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 82 NORTH AMERICA HEART FAILURE DEVICES MARKET REVENUE,
BASED ON END-USERS, (2021-2029) (\$MN)

TABLE 83 NORTH AMERICA HEART FAILURE DEVICES MARKET REVENUE,
BASED ON SURGERY, (2021-2029) (\$MN)

TABLE 84 NORTH AMERICA HEART FAILURE DEVICES MARKET REVENUE,
BASED ON COUNTRY, (2021-2029) (\$MN)

TABLE 85 U.S. SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE
(ASP) (\$) & NO. OF UNITS SOLD (2022)

TABLE 86 REST OF N.A. SELECTED HEART FAILURE DEVICES AVERAGE
SELLING PRICE (ASP) (\$) & NO. OF UNITS SOLD(2022)

TABLE 87 EUROPE HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP)
(\$) & NO. OF UNITS SOLD (2022)

TABLE 88 EUROPE HEART FAILURE DEVICES MARKET REVENUE, BASED ON
PRODUCT (2021-2029) (\$MN)

TABLE 89 EUROPE CARDIAC RHYTHM PRODUCTS MARKET REVENUE, BASED
ON PRODUCT TYPE (2021-2029) (\$MN)

TABLE 90 EUROPE CRT MARKET REVENUE, BASED ON PRODUCT TYPE
(2021-2029) (\$MN)

TABLE 91 EUROPE ICD MARKET REVENUE, BASED ON PRODUCT TYPE
(2021-2029) (\$MN)

TABLE 92 EUROPE PACEMAKER MARKET REVENUE, BASED ON PRODUCT
TYPE (2021-2029) (\$MN)

TABLE 93 EUROPE CAD MARKET REVENUE, BASED ON PRODUCT TYPE
(2021-2029) (\$MN)

TABLE 94 EUROPE VAD MARKET REVENUE, BASED ON PRODUCT TYPE,
(2021-2029) (\$MN)

TABLE 95 EUROPE SHD MARKET REVENUE, BASED ON PRODUCTS (2021-2029)
(\$MN)

TABLE 96 EUROPE REPAIR DEVICES MARKET REVENUE, BASED ON PRODUCT
TYPE, (2021-2029) (\$MN)

TABLE 97 EUROPE REPLACEMENT DEVICES MARKET REVENUE, BASED ON
PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 98 EUROPE SURGICAL VALVE MARKET REVENUE, BASED ON PRODUCT
TYPE, (2021-2029) (\$MN)

TABLE 99 EUROPE TRANSCATHETER VALVE MARKET REVENUE, BASED ON
PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 100 EUROPE HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USERS, (2021-2029) (\$MN)

TABLE 101 EUROPE HEART FAILURE DEVICES MARKET REVENUE, BASED ON SURGERY, (2021-2029) (\$MN)

TABLE 102 EUROPE HEART FAILURE DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) (\$MN)

TABLE 103 GERMANY SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) (\$) & NO. OF UNITS SOLD(2022)

TABLE 104 FRANCE SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) (\$) & NO. OF UNITS SOLD(2022)

TABLE 105 ITALY SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) (\$) & NO. OF UNITS SOLD(2022)

TABLE 106 THE REST OF EUROPE SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) (\$) & NO. OF UNITS SOLD(2022)

TABLE 107 APAC HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCT (2021-2029) (\$MN)

TABLE 108 APAC CARDIAC RHYTHM PRODUCTS MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) (\$MN)

TABLE 109 APAC CRT MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029)(\$MN)

TABLE 110 APAC ICD MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029)(\$MN)

TABLE 111 APAC PACEMAKER MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) (\$MN)

TABLE 112 APAC CAD MARKET REVENUE, BASED ON PRODUCTS (2021-2029)(\$MN)

TABLE 113 APAC VAD MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 114 APAC SHD MARKET REVENUE, BASED ON PRODUCTS (2021-2029) (\$MN)

TABLE 115 APAC REPAIR DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 116 APAC REPLACEMENT DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 117 APAC SURGICAL VALVE MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 118 APAC TRANSCATHETER VALVE MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 119 APAC HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-

USERS, (2021-2029) (\$MN)

TABLE 120 APAC HEART FAILURE DEVICES MARKET REVENUE, BASED ON SURGERY, (2021-2029) (\$MN)

TABLE 121 ASIA-PACIFIC HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) (\$) & NO. OF UNITS SOLD(2022)

TABLE 122 APAC HEART FAILURE DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) (\$MN)

TABLE 123 JAPAN SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) (\$) & NO. OF UNITS SOLD(2022)

TABLE 124 CHINA SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) (\$) & NO. OF UNITS SOLD(2022)

TABLE 125 INDIA SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) (\$) & NO. OF UNITS SOLD(2022)

TABLE 126 REST OF APAC SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) (\$) & NO. OF UNITS SOLD(2022)

TABLE 127 ROW HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCT (2021-2029) (\$MN)

TABLE 128 ROW CARDIAC RHYTHM PRODUCTS MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) (\$MN)

TABLE 129 ROW CRT MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029)(\$MN)

TABLE 130 ROW ICD MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029)(\$MN)

TABLE 131 ROW PACEMAKER MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) (\$MN)

TABLE 132 ROW CAD MARKET REVENUE, BASED ON PRODUCTS (2021-2029) (\$MN)

TABLE 133 ROW VAD MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 134 ROW SHD MARKET REVENUE, BASED ON PRODUCTS (2021-2029)(\$MN)

TABLE 135 ROW REPAIR DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 136 ROW REPLACEMENT DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 137 ROW SURGICAL VALVE MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 138 ROW TRANSCATHETER VALVE MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) (\$MN)

TABLE 139 ROW HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USERS, (2021-2029) (\$MN)

TABLE 140 ROW HEART FAILURE DEVICES MARKET REVENUE, BASED ON SURGERY, (2021-2029) (\$MN)

TABLE 141 ROW HEART FAILURE DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) (\$MN)

TABLE 142 ROW HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) (\$) & NO. OF UNITS SOLD(2022)

TABLE 143 BRAZIL SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) (\$) & NO. OF UNITS SOLD(2022)

TABLE 144 REST OF LATAM SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) (\$) & NO. OF UNITS SOLD(2022)

TABLE 145 MIDDLE EAST AND AFRICA SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) (\$) & NO. OF UNITS SOLD(2022)

TABLE 146 PRODUCT APPROVALS (2021 - 2022)

TABLE 147 ACQUISITIONS (2021 - 2022)

TABLE 148 PRODUCT LAUNCH (2021 - 2022)

TABLE 149 INVESTMENT AND FUNDING (2021 - 2022)

TABLE 150 OTHER DEVELOPMENTS (2021 - 2022)

TABLE 151 ABBOTT, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q3) (\$MN)

TABLE 152 ABBOTT, INC.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022)(Q3) (\$MN)

TABLE 153 ABBOTT, INC.: MEDICAL DEVICES SEGMENT REVENUE, BASED ON SUB-SEGMENT, (2020-2022)(Q3) (\$MN)

TABLE 154 ABBOTT, INC.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022)(Q3) (\$MN)

TABLE 155 ABIOMED: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q2) (\$MN)

TABLE 156 ABIOMED: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) (\$MN)

TABLE 157 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q3)) (\$MN)

TABLE 158 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022)(Q3) (\$MN)

TABLE 159 BOSTON SCIENTIFIC CORP.: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENT, (2020-2022)(Q3) (\$MN)

TABLE 160 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022(Q3)) (\$MN)

TABLE 161 EDWARDS LIFESCIENCE: TOTAL REVENUE AND R&D EXPENSES,
(2020-2022)(Q3)) (\$MN)

TABLE 162 EDWARDS LIFESCIENCE: TOTAL REVENUE, BASED ON SEGMENTS,
(2020-2022(Q3)) (\$MN)

TABLE 163 EDWARDS LIFE SCIENCE: TOTAL REVENUE, BASED ON
GEOGRAPHY, (2020-2022(Q3)) (\$MN)

TABLE 164 GETINGE: TOTAL REVENUE AND R&D EXPENSES,
(2020-2022)(Q3))(\$MN)

TABLE 165 GETINGE: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022(Q3))
(\$MN)

TABLE 166 GETINGE: TOTAL REVENUE, BASED ON GEOGRAPHY,
(2020-2022(Q3)) (\$MN)

TABLE 167 MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES,
(2020-2022)(Q2) (\$MN)

TABLE 168 MEDTRONIC, PLC: TOTAL REVENUE, BASED ON SEGMENTS,
(2020-2022)(Q2) (\$MN)

TABLE 169 MEDTRONIC, PLC: CARDIOVASCULAR TOTAL REVENUE, BASED ON
SUB-SEGMENTS, (2022-2022)(Q2) (\$MN)

TABLE 170 MEDTRONIC, PLC: TOTAL REVENUE, BASED ON GEOGRAPHY,
(2021-2023)(Q2) (\$MN)

TABLE 171 MICROPORT SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D
EXPENSES, (2019-2021) (\$MN)

TABLE 172 MICROPORT SCIENTIFC CORPORATION: TOTAL REVENUE, BASED
ON SEGMENTS, (2019-2021) (\$MN)

TABLE 173 MICROPORT SCIENTIFC CORPORATION TOTAL REVENUE, BASED
ON GEOGRAPHY, (2019-2021) (\$MN)

TABLE 174 TELEFLEX, INC.: TOTAL REVENUE AND R&D EXPENSES,
(2020-2022)(Q3) (\$MN)

TABLE 175 TELEFLEX, INC.: TOTAL REVENUE, BASED ON SEGMENTS,
(2020-2022)(Q3) (\$MN)

TABLE 176 TELEFLEX, INC.: TOTAL REVENUE, BASED ON GEOGRAPHY,
(2020-2022)(Q3) (\$MN)

List Of Figures

LIST OF FIGURES

FIGURE 1 HEART FAILURE DEVICES GLOBAL MARKET REVENUE AND SHARE, BASED ON REGION (2021-2029) (\$MN) (%)

FIGURE 2 RESEARCH METHODOLOGY: HEART FAILURE DEVICES GLOBAL MARKET

FIGURE 3 HEART FAILURE DEVICES GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH

FIGURE 4 HEART FAILURE DEVICES GLOBAL MARKET: FORECASTING MODEL

FIGURE 5 HEART FAILURE DEVICES GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION

FIGURE 6 HEART FAILURE DEVICES GLOBAL MARKET SEGMENTATION

FIGURE 7 PRODUCTS MARKET SEGMENTATION

FIGURE 8 MARKET DYNAMICS

FIGURE 9 HEART FAILURE DEVICES GLOBAL MARKET: PORTER'S ANALYSIS

FIGURE 10 CARDIAC ASSIST DEVICES MARKET: PATENT FILING BY MAJOR PLAYERS (2018-2022)

FIGURE 11 HEART VALVE DEVICES MARKET: PATENT FILING BY MAJOR PLAYERS (2018-2022)

FIGURE 12 VENTRICULAR ASSIST DEVICES MARKET: PATENT FILING BY MAJOR PLAYERS (2018-2022)

FIGURE 13 HEART FAILURE DEVICES GLOBAL MARKET: SUPPLY CHAIN ANALYSIS

FIGURE 14 HEART FAILURE DEVICES GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)

FIGURE 15 VENTRICULAR ASSIST DEVICES (VAD) GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)

FIGURE 16 INTRA-AORTIC BALLOON PUMP (IABP) GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)

FIGURE 17 CARDIAC RESYNCHRONIZATION THERAPY GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, (2022) (%)

FIGURE 18 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)

FIGURE 19 SINGLE-CHAMBER IMPLANTABLE CARDIOVERTER DEFIBRILLATORS GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)

FIGURE 20 DUAL-CHAMBER IMPLANTABLE CARDIOVERTER DEFIBRILLATORS GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)

FIGURE 21 PACEMAKER GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)

FIGURE 22 SINGLE CHAMBER PACEMAKER GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)

FIGURE 23 DUAL CHAMBER PACEMAKER GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)

FIGURE 24 ANNULOPLASTY REPAIR DEVICES GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)

FIGURE 25 OCCLUDERS GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)

FIGURE 26 MECHANICAL HEART VALVE GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)

FIGURE 27 U.S. PVAD MARKET PENETRATION, (2022) (%)

FIGURE 28 ITALY PVAD MARKET PENETRATION, (2022) (%)

FIGURE 29 GERMANY PVAD MARKET PENETRATION, (2022) (%)

FIGURE 30 FRANCE PVAD MARKET PENETRATION, (2022) (%)

FIGURE 31 JAPAN PVAD MARKET PENETRATION, (2022) (%)

FIGURE 32 U.S. IABP TAM & MARKET PENETRATION, (2022) (%)

FIGURE 33 ITALY IABP TAM & MARKET PENETRATION, (2022) (%)

FIGURE 34 GERMANY IABP TAM & MARKET PENETRATION, (2022) (%)

FIGURE 35 FRANCE IABP TAM & MARKET PENETRATION, (2022) (%)

FIGURE 36 JAPAN IABP TAM & MARKET PENETRATION, (2022) (%)

FIGURE 37 GLOBAL TAVR TAM, MARKET PENETRATION, AND NUMBER OF PROCEDURES PERFORMED, (2022)

FIGURE 38 U.S. TAVR TAM, MARKET PENETRATION, AND NUMBER OF PROCEDURES PERFORMED, (2022)

FIGURE 39 CHINA TAVR TAM, MARKET PENETRATION, AND NUMBER OF PROCEDURES PERFORMED, (2022)

FIGURE 40 GLOBAL TMVR AND TMVR TAM, MARKET PENETRATION, AND NUMBER OF PROCEDURES PERFORMED, (2022)

FIGURE 41 GLOBAL TPVR TAM, MARKET PENETRATION, AND NUMBER OF PROCEDURES PERFORMED, (2022)

FIGURE 42 U.S. BAT MARKET PENETRATION, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED, (2022)

FIGURE 43 5 E.U. COUNTRIES BAT MARKET PENETRATION, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED, (2022)

FIGURE 44 5 APAC COUNTRIES BAT MARKET PENETRATION, AND OPPORTUNITY, (2022)

FIGURE 45 HEART FAILURE DEVICES GLOBAL MARKET SHARE, BASED ON

PRODUCT, (2022 VS 2029) (%)

FIGURE 46 CARDIAC RHYTHM PRODUCTS GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)

FIGURE 47 ICD GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)

FIGURE 48 PACEMAKER GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)

FIGURE 49 NYHA CLASSIFICATION I II, DEVICE-BASED FLOW CHART FOR PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

FIGURE 50 NYHA CLASSIFICATION III, DEVICE-BASED FLOW CHART FOR PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

FIGURE 51 NYHA CLASSIFICATION IV, DEVICE-BASED FLOW CHART FOR PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

FIGURE 52 CAD GLOBAL MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)

FIGURE 53 VAD GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)

FIGURE 54 STRUCTURAL HEART DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)

FIGURE 55 STRUCTURAL HEART REPAIR DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022) (%)

FIGURE 56 TMVR GLOBAL MARKET SHARE, BASED ON REGION, (2022 VS 2029) (%)

FIGURE 57 REPLACEMENT DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)

FIGURE 58 SURGICAL VALVE REPLACEMENT DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)

FIGURE 59 TRANSCATHETER VALVE REPLACEMENT DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)

FIGURE 60 HEART FAILURE DEVICES GLOBAL MARKET SHARE, BASED ON SURGERY (2022 VS 2029) (%)

FIGURE 61 OPEN SURGERY GLOBAL MARKET SHARE, BASED ON REGION, (2022 VS 2029) (%)

FIGURE 62 HEART FAILURE DEVICES GLOBAL MARKET SHARE, BASED ON END-USERS (2022 VS 2029) (%)

FIGURE 63 HOSPITALS GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)

FIGURE 64 HEART FAILURE DEVICES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) (\$MN), CAGR (%)

FIGURE 65 HEART FAILURE DEVICES GLOBAL MARKET SHARE BASED ON REGION AND MARKET REVENUE BY COUNTRY, (2022) (%) (\$MN)

FIGURE 66 NORTH AMERICA HEART FAILURE DEVICES MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)

FIGURE 67 NORTH AMERICA CARDIAC RHYTHM PRODUCTS AND CRT MARKET REVENUE, BASED ON PRODUCT, (2022) (\$MN)

FIGURE 68 NORTH AMERICA ICD MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)

FIGURE 69 NORTH AMERICA PACEMAKER MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)

FIGURE 70 NORTH AMERICA CAD MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)

FIGURE 71 NORTH AMERICA VAD MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)

FIGURE 72 NORTH AMERICA SHD MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)

FIGURE 73 NORTH AMERICA REPAIR DEVICES MARKET SHARE, BASED ON PRODUCT TYPE, (2022) (%)

FIGURE 74 NORTH AMERICA REPLACEMENT DEVICES MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)

FIGURE 75 NORTH AMERICA SURGICAL VALVE MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)

FIGURE 76 NORTH AMERICA TRANSCATHETER VALVE MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)

FIGURE 77 NORTH AMERICA HEART FAILURE DEVICES MARKET SHARE, BASED ON END-USERS, (2022 VS 2029) (%)

FIGURE 78 NORTH AMERICA HEART FAILURE DEVICES MARKET SHARE, BASED ON SURGERY, (2022 VS 2029) (%)

FIGURE 79 NORTH AMERICA HEART FAILURE DEVICES MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)

FIGURE 80 U.S. HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS BASED ON PRODUCT TYPE (2022 VS 2029) (\$MN)

FIGURE 81 U.S. CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) (\$MN)

FIGURE 82 U.S. HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) (\$MN)

FIGURE 83 THE REST OF THE NORTH AMERICA HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS,

BASED ON PRODUCT TYPE (2022 VS 2029) (\$MN)

FIGURE 84 REST OF NORTH AMERICA CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) (\$MN)

FIGURE 85 REST OF NORTH AMERICA HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) (\$MN)

FIGURE 86 EUROPE HEART FAILURE DEVICES MARKET SHARE, BASED ON PRODUCT (2022 VS 2029) (%)

FIGURE 87 EUROPE CARDIAC RHYTHM PRODUCTS AND CRT MARKET REVENUE, BASED ON PRODUCT, (2022) (\$MN)

FIGURE 88 EUROPE ICD MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)

FIGURE 89 EUROPE PACEMAKER MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)

FIGURE 90 EUROPE CAD MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)

FIGURE 91 EUROPE VAD MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)

FIGURE 92 EUROPE SHD MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)

FIGURE 93 EUROPE REPAIR DEVICES MARKET SHARE, BASED ON PRODUCT TYPE, (2022) (%)

FIGURE 94 EUROPE REPLACEMENT DEVICES MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)

FIGURE 95 EUROPE SURGICAL VALVE MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)

FIGURE 96 EUROPE TRANSCATHETER VALVE MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)

FIGURE 97 EUROPE HEART FAILURE DEVICES MARKET SHARE, BASED ON END-USERS, (2022 VS 2029) (%)

FIGURE 98 EUROPE HEART FAILURE DEVICES MARKET SHARE, BASED ON END-USERS, (2022 VS 2029) (%)

FIGURE 99 EUROPE HEART FAILURE DEVICES MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)

FIGURE 100 GERMANY HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) (\$MN)

FIGURE 101 GERMANY CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) (\$MN)

FIGURE 102 GERMANY HEART FAILURE DEVICES MARKET REVENUE, BASED

ON END-USER & SURGERY (2022 VS 2029) (\$MN)

FIGURE 103 FRANCE HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) (\$MN)

FIGURE 104 FRANCE CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) (\$MN)

FIGURE 105 FRANCE HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) (\$MN)

FIGURE 106 ITALY HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) (\$MN)

FIGURE 107 ITALY CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) (\$MN)

FIGURE 108 ITALY HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) (\$MN)

FIGURE 109 REST OF EUROPE HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) (\$MN)

FIGURE 110 REST OF EUROPE CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) (\$MN)

FIGURE 111 REST OF EUROPE HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) (\$MN)

FIGURE 112 APAC HEART FAILURE DEVICES MARKET SHARE, BASED ON PRODUCT (2022 VS 2029) (%)

FIGURE 113 APAC CARDIAC RHYTHM PRODUCTS AND CRT MARKET REVENUE, BASED ON PRODUCT, (2022) (\$MN)

FIGURE 114 APAC ICD MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)

FIGURE 115 APAC PACEMAKER MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)

FIGURE 116 APAC CAD MARKET SHARE, BASED ON PRODUCTS, (2022 VS 2029) (%)

FIGURE 117 APAC VAD MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)

FIGURE 118 APAC SHD MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)

FIGURE 119 APAC REPAIR DEVICES MARKET SHARE, BASED ON PRODUCT TYPE, (2022) (%)

FIGURE 120 APAC REPLACEMENT DEVICES MARKET SHARE, BASED ON

PRODUCT TYPE, (2022 VS 2029) (%)

FIGURE 121 APAC SURGICAL VALVE MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)

FIGURE 122 APAC TRANSCATHETER VALVE MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)

FIGURE 123 APAC HEART FAILURE DEVICES MARKET SHARE, BASED ON END-USERS, (2022 VS 2029) (%)

FIGURE 124 APAC HEART FAILURE DEVICES MARKET SHARE, BASED ON SURGERY, (2022 VS 2029) (%)

FIGURE 125 APAC HEART FAILURE DEVICES MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)

FIGURE 126 JAPAN HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) (\$MN)

FIGURE 127 JAPAN CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) (\$MN)

FIGURE 128 JAPAN HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) (\$MN)

FIGURE 129 CHINA HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) (\$MN)

FIGURE 130 CHINA CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) (\$MN)

FIGURE 131 CHINA HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) (\$MN)

FIGURE 132 INDIA HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) (\$MN)

FIGURE 133 INDIA CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) (\$MN)

FIGURE 134 INDIA HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) (\$MN)

FIGURE 135 REST OF APAC FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) (\$MN)

FIGURE 136 REST OF APAC CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) (\$MN)

FIGURE 137 REST OF APAC HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) (\$MN)

FIGURE 138 ROW HEART FAILURE DEVICES MARKET SHARE, BASED ON PRODUCT (2022 VS 2029) (%)

FIGURE 139 ROW CARDIAC RHYTHM PRODUCTS AND CRT MARKET REVENUE, BASED ON PRODUCT TYPE, (2022) (\$MN)

FIGURE 140 ROW ICD MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)

FIGURE 141 ROW PACEMAKER MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)

FIGURE 142 ROW CAD MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)

FIGURE 143 ROW VAD MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)

FIGURE 144 ROW SHD MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)

FIGURE 145 ROW REPAIR DEVICES MARKET SHARE, BASED ON PRODUCT TYPE, (2022) (\$MN)

FIGURE 146 ROW REPLACEMENT DEVICES MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)

FIGURE 147 ROW SURGICAL VALVE REPLACEMENT MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)

FIGURE 148 ROW TRANSCATHETER VALVE MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)

FIGURE 149 ROW HEART FAILURE DEVICES MARKET SHARE, BASED ON END-USERS, (2022 VS 2029) (%)

FIGURE 150 ROW HEART FAILURE DEVICES MARKET SHARE, BASED ON END-USERS, (2022 VS 2029) (%)

FIGURE 151 ROW HEART FAILURE DEVICES MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)

FIGURE 152 BRAZIL HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) (\$MN)

FIGURE 153 BRAZIL CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) (\$MN)

FIGURE 154 BRAZIL HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) (\$MN)

FIGURE 155 REST OF LATAM HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) (\$MN)

FIGURE 156 REST OF LATAM CAD & SHD MARKET REVENUE, BASED ON

PRODUCTS (2022 VS 2029) (\$MN)

FIGURE 157 REST OF LATAM HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) (\$MN)

FIGURE 158 MIDDLE EAST AND AFRICA HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) (\$MN)

FIGURE 159 MIDDLE EAST AND AFRICA CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) (\$MN)

FIGURE 160 MIDDLE EAST AND AFRICA HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) (\$MN)

FIGURE 161 KEY GROWTH STRATEGIES, (2021-2022)

FIGURE 162 SWOT: ABBOTT, INC.

FIGURE 163 SWOT: ABIOMED

FIGURE 164 SWOT: BIOTRONIK

FIGURE 165 SWOT: BOSTON SCIENTIFIC CORPORATION

FIGURE 166 SWOT: CORCYM

FIGURE 167 SWOT: EDWARDS LIFESCIENCES

FIGURE 168 SWOT: GETINGE

FIGURE 169 SWOT: MEDTRONIC, PLC

FIGURE 170 SWOT: MICROPORT SCIENTIFIFC CORPORATION

FIGURE 171 SWOT: TELEFLEX

I would like to order

Product name: Heart Failure Devices Global Market - Forecast to 2029

Product link: <https://marketpublishers.com/r/H46F9603C2FFEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H46F9603C2FFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970